Journal articles on the topic 'Villa Alejandro'

PurposeThis paper analyses the incremental housing process developed at Villa Verde, a housing project designed by the Chilean architecture firm Elemental, whose director Alejandro Aravena received the Pritzker Prize in 2016. This project is conceived within a social housing framework and designed as an affordable “half-house” to be incrementally extended by the owners.Design/methodology/approachThis paper is based on research undertaken in August 2017 with data obtained through site surveys, trace analysis, interviews with 32 residents and photographic surveys. The researchers mapped the modifications made by all households at Villa Verde in the four years after occupation.FindingsThe strategy of designing a formal framework for informal additions has generally been successful with most houses undergoing substantial expansion to a high standard of construction. The paper raises concerns regarding the settlement's urban design, response to local climate and the quality of shared open space. We also find evidence of over-development as informal additions extend across front and rear yards that are in some cases fully enclosed.Originality/valueThis project is critiqued within the context of a long series of architectural attempts to harness the productive capacities of self-help housing. Villa Verde engages the freedom to build in a self-organised manner within a formal framework. But what will stop these additions from escalating into a “slum”?

Inserido no campo das artes visuais, o cinema pode ser definido como uma prática arquitetônica, como um agente na construção das visões das cidades. Mais do que ser o local onde transcorre a ação, os espaços fílmicos podem ser trabalhados como elementos potentes para descortinar o passado, trazendo à tona memórias e dinâmicas menos explícitas, fazendo ver e ouvir processos que a narrativa oficial buscou ocultar. Com sensibilidade, a construção espacial do documentário AU3 – Autopista Central (Alejandro Hartmann, 2010) coloca em cena a tensão social e urbana que atravessam diferentes períodos da história de Buenos Aires. Através do olhar atento aos espaços e moradores de Villa Urquiza, AU3 confere visibilidade aos processos de exclusão da cidade e também à inominável violência da ditadura, oferecendo uma mirada contra a tentativa de apagar narrativas indesejadas à história oficial.

Hipotiroidismo y embarazo Dr. Marcos S. Abalovich ¿Qué conducta tomar con la mujer que busca embarazo y tiene TSH entre 2,5 y 4,5 mUI/L? y ¿si va a técnicas de reproducción asistida? Dr. Marcos S. Abalovich Interpretación de pruebas de función tiroidea Gabriela Brenta Obesidad, dislipidemia y patología tiroidea: ¿cuál es la relación? Gabriela Brenta Dificultades en el tratamiento del hipotiroidismo Carlos Alfonso Builes Barrera Tirotoxicosis en todas sus presentaciones Luz Ángela Casas Figueroa Oftalmopatía de Graves Alejandro Alberto Castellanos Pinedo Ecografía en patología tiroidea difusa John Jairo Duque Ossman Hipotiroidismo subclínico, ¿porqué no tratar? Dr. Harold H. García Touchíe Enfermedad de Graves-Basedow ¿Es la terapia con I131 la mejor opción? José Luis Torres Grajales Implicaciones clínicas del BETHESDA, TIRADS, y los test de expresión genética en el diagnóstico y seguimiento del nódulo tiroideo Dra. Adriana M. Vázquez Seguimiento del paciente con cáncer diferenciado de tiroides Dra. Adriana M. Vázquez Terapia con yodo radioactivo en cáncer de tiroides Hooverman Villa Velásquez Características clínicas, histopatológicas y terapéuticas del cáncer de tiroides en Colombia: Registro Nacional Específico Wandurraga EA, Marín LF, Natera AK, Gómez CM, Niño F, Arenas HM, Castellanos R, López NA, De La Portilla D, Feriz KM, Pinzón A, Dueñas JP, Abreu A, Fierro LF, Pinzón JB, Torres JL, Palacio AF, Sánchez L, García RE Abordaje quirúrgico del paciente con carcinoma de tiroides Sergio Fabián Zúñiga Pavia

I-1 RESPUESTA PARADOJICA AL TRATAMIENTO ANTITUBERCULOSO EN UN PACIENTE CON TUBERCULOSIS MENINGEA Y ESPINAL, A PROPOSITO DE UN CASO (RESTREPO ANDREA, CLAVIJO ABSALÓN, GÓMEZ DIANA, AGUDELO CARLOS ANDRÉS) I-2 TRATAMIENTO EXITOSO CON FOSCARNET EN LESIONES ATÍPICAS DE VIRUS HERPES SIMPLE EN COINFECCIÓN CON VIRUS DE INMUNODEFICIENCIA HUMANA (RODRIGUEZ HERRERA DANIELA, PATIÑO GIRALDO SANTIAGO) I-3 LESIÓN RENAL AGUDA SECUNDARIO A TOXINA DE LONOMIA OBLIQUA (ARSANIOS DANIEL, QUINTERO ELIAS, SANTOYO NICOLÁS, MUÑOZ CARLOS) I-4 PIOMIOSITIS EN MUSLO POR PSEUDOMONAS (COGOLLO MARYSABEL, BORRÉ DIANA) I-5 SÍNDROME HEMOFAGOCÍTICO COMO MANIFESTACIÓN DE SÍNDROME DE WEIL (ARAGÓN DIANA, GUTIÉRREZ MARGARITA, CONCHA DIANA, OSPINA MARÍA, SÁNCHEZ ALEXANDER, ENCISO LEONARDO) I-6 DISFUNCION MULTIORGANICA POR ABSCESO PERINEFITICO BILATERAL MAS ABSCESO HEPATICO (COGOLLO GONZÁLEZ MARYSABEL, ALVARADO CUETO DANIEL, JULIO NARVAEZ LUIS CARLOS) I-7 ANGINA DE LUDWIG CON COMPROMISO DE VÍA AÉREA EN PACIENTE AÑOSA (ORDOÑEZ KARINA, ARTETA SHEILA) I-8 TUBERCULOSIS MENINGEA Y OTRAS MANIFESTACIONES INFRECUENTES DE TUBERCULOSIS DISEMINADA EN HUÉSPED INMUNOCOMPETENTE (DE LA VEGA FERNANDO, VARGAS-HERNÁNDEZ MARÍA, PACHECOCUMPLIDO ARNULFO, BLANCO-REYES SILVIA, RODRIGUEZ-YANEZ TOMÁS) I-9 ESPONDILODISCITIS INFECCIOSA SECUNDARIO A CUSHING FARMACOLOGICO (KARINA ORDOÑEZ, ALAN SEPÚLVEDA, GERMAN VICIOSO) I-10 ANAPLASMOSIS GRANULOCITOTRÓPICA HUMANA: ZOONOSIS EMERGENTE EN PACIENTE INMUNOSUPRIMIDO POR VIH (DE LA VEGA FERNANDO, GUTIÉRREZ-CUESTA JORGE, MARTÍNEZPINTO JUAN, PACHECO-CUMPLIDO ARNULFO, BLANCO-REYES SILVIA, RODRIGUEZ-YANEZ TOMÁS) I-11 VENTRICULITIS POR CITOMEGALOVIRUS EN PACIENTE INMUNOCOMPROMETIDO AFRICANO (LOPEZ FERNEY ALBEIRO, AFRICANO LOPEZ HOLMAN LEONARDO) I-12 ELEVACIÓN TRANSAMINASAS E INFECCION POR EPSTEIN-BARR, UNA ENTIDAD PARA NO OLVIDAR (GARCÍA DIANA, ALZA JHONGERT, POVEDA GUSTAVO, ALZA LYZINHAWER) I-13 TUBERCULOSIS HEPÁTICA AISLADA EN PACIENTE INMUNOCOMPETENTE: REPORTE DE CASO (OCAMPO MARIA ISABEL, ARENAS MAYRA, FONSECA JUAN FERNANDO, RUMBO JOSÉ ALEJANDRO, DAVID DAVID, SALAZAR LUKAS, BUSTOS MARLON) I-14 LOXOCELISMO CUTÁNEO NECRÓTICO (MARÍA ÁNGELA CASTELLANOS-GUTIÉRREZ, DEISY RODRIGUEZ-BERDUGO) I-15 BACTEREMIA POR ACINETOBACTER URSINGII EN PACIENTE INMUNOCOMPETENTE (MARTÍN DANIEL, BARRAGÁN ANDRÉS, GARZÓN DIANA) I-16 GLUCANTIME Y PROLONGACIÓN DEL QTC: UNA COMBINACIÓN FATAL (DUQUE LAURA, LÓPEZ HELBER, NARANJO SEBASTIÁN, ARISTIZÁBAL JULIÁN, DUQUE MAURICIO) I-17 ASPERIGILOSIS INVASIVA INTESTINAL, UN GERMEN UBICUO EN UNA LOCALIZACIÓN INUSUAL (NARANJO JULIÁN, ACOSTA MARÍA FERNANDA, ARAGÓN DIANA, GUERRA JOAQUÍN, NOREÑA IVÁN) I-18 ENDOCARDITIS INFECCIOSA POR GEMELLA SANGUINIS: PRIMER REPORTE DE CASO EN COLOMBIA (ESPINOSA-SERNA JUAN SEBASTIÁN, DUARTE LUISA, NOREÑA IVÁN. ) I-19 MENINGOENCEFALITIS AGUDA POR STREPTOCOCCUS AGALACTIAE EN ADULTO JOVEN (ÁLVAREZ CAMILO, RESTREPO CARLOS, NAVARRETE LINDA, PRIETO JAVIER, CUERVO JESSICA, MÉNDEZ JUAN) I-20 CANDIDIASIS ESOFAGICA EN PACIENTE CON INMUNODEFICIENCIA STAT-1 (CÁRDENAS LAURA, DONOSO LAURA, GÓMEZ PAULA, JOHNSON NATALIA, NOVA DORA, TORRALBA FELIPE) I-21 MASA OVÁRICA, ASCITIS Y CA 125 ELEVADO, TAMBIÉN PUEDE SER TUBERCULOSIS (NARANJO JULIO, MORALES XIMENA, CORTES CAMILO) I-22 CRIPTOCOCOSIS DISEMINADA POR CRYPTOCOCCUS GATTII (MÉNDEZ JORGE, RINCÓN SONIA, TOLE CAMILA, SANDOVAL LINA, BUSTOS MARLON) I-23 HISTOPLASMOSIS DISEMINADA EN PACIENTE DIABÉTICO (CONTRERAS ALEJANDRA, CORTÉS CAMILO) I-24 HISTOPLASMOSIS DISEMINADA EN INMUNOCOMPETENTES (TRUJILLO DANIELA, RUIZ LUIS MIGUEL, RESTREPO RICARDO, VEGA JULIANA) I-25 ABSCESO ESPLÉNICO DEBIDO A ENTEROBACTER AEROGENES (MAYORGA CAROL, CHAAR ALDAIR, CALDERÓN MAURICIO, VERA JUAN, MARTIN DANIEL, VESGA DANIEL) I-26 SÍNDROME DEL ABSCESO HEPÁTICO POR KLEBSIELLA PNEUMONIAE INVASORA (TORRES BUSTAMANTE ÁNGELA MARÍA, CASTAÑEDA CAMACHO HÉCTOR ANDRÉS. ) I-27 TUBERCULOSIS HEPATICA AISLADA: UNA CAUSA RARA DE TUMORES HEPATICOS (DE LA VEGA FERNANDO, CÓRDOBA-CABALLERO ANGIE, RODRIGUEZ-YANEZ TOMÁS, GARCÍA-PRADA CAMILO) I-28 HISTOPLASMOSIS PERITONEAL EN UN PACIENTE INMUNOCOMPROMETIDO (SIERRA UMAÑA SEBASTIÁN FELIPE, ROSERO PAREDES SILVIO JAVIER, URRUTIA CORREDOR LAURA CAMILA, BARRIOS VILLEGAS JUAN ESTEBAN, ARCE CUERVO JULIANA) I-29 PRESENTACIÓN INUSUAL DE CRIPTOCOCOSIS CEREBRAL COMO LESIÓN TUMORAL INTRACRANEAL EN PACIENTE CON ANTECEDENTE DE GLIOBLASTOMA CEREBRAL (REYES TOLEDO RAÚL, MESA ZULUAGA MARIA, GÓMEZ QUINTERO CARLOS, RIVAS PILAR) I-30 EMPIEMA PLEURAL POR SALMONELLA EN PACIENTE CON LUPUS ERITEMATOSO SISTÉMICO (CONTRERAS ALEJANDRA, NOVOA DANNY) I-31 RECIDIVA DE LEPRA, EN PACIENTE INICIALMENTE DIAGNOSTICADO CON DERMATITIS EXFOLIATIVA ASOCIADA A MEDICACIÓN ANTITUBERCULOSA (MESA ZULUAGA MARÍA ALEJANDRA, MEDINA AHUMADA PATRICIA) I-32 MICOBACTERIA DE CRECIMIENTO RÁPIDO EN UN PACIENTE CON USO DE ANTI-TNF (GUTIÉRREZ-BOLAÑOS JOHANN, VARELA DIANA-CRISTINA, GARCÍA-RINCÓN CRISTIAN-IVÁN) I-33 PARACOCCIDIOIDOMICOSIS COMO CAUSA DE INSUFICIENCIA SUPRARRENAL, UN RETO DIAGNOSTICO PARA UNA CAUSA INSOSPECHADA (SANTACRUZ DEVIA JUAN CAMILO, PARAMO DÍAZ LAURA ISABEL, NARANJO JULIÁN, ARAGÓN DIANA MARCELA) I-34 HISTOPLASMOSIS DISEMINADA EN PACIENTE CON LUPUS ERITEMATOSO SISTEMICO (VISUALIZACIÓN DIRECTA EN MEDULA ÓSEA) (GRANELA KATYA, BROCHADO LEONARDO) I-35 PAPEL DEL VIRUS EPSTEIN BARR EN LA PATOGENIA DE LA ENCEFALOMIELITIS AGUDA DISEMINADA (LUIS DULCEY, JONATHAN PINEDA, WILLIAM GONZÁLEZ, RODOLFO MARTHEYN, RAIMONDO CALTAGIRONE, BELKIS MENONI, PEDRO QUIJADA. ) I-36 INFECCIÓN FÚNGICA INVASORA EN PACIENTE NO NEUTROPÉNICO (GÓMEZ PACHÓN CAMILO ANDRÉS, BRAVO OJEDA JUAN SEBASTIÁN, GONZÁLEZ SALEBE VÍCTOR MANUEL, RAMOS CUELLAR GINA ALEXANDRA, PÉREZ FRANCO JAIRO ENRIQUE) I-37 PROFILAXIS ANTIBIÓTICA EN PROCEDIMIENTOS ODONTOLÓGICOS PARA PREVENIR ENDOCARDITIS BACTERIANA: UNA REVISIÓN BIBLIOMÉTRICA (MUÑOZ LOMBO JENNY PATRICIA, GIL GUTIÉRREZ CARLOS ENRIQUE, GIL RODRÍGUEZ KARLA JOHANNA, GONZÁLEZ AROSEMENA JULIANA, GUERRERO REYNA FELIPE) I-38 EMPIEMA NECESSITATIS POR SALMONELLA CON COMPLICACION CON QUILOTORAX (PUENTES CASTRILLON MARIA ELCY, CORREA ALDANA JOHN JAIRO, DOMINGUEZ RUIZ JUAN DIEGO, PUENTES CASTRILLON JOSE JOVANY, SALINAS CORTES DIEGO, ZULUAGA BEDOYA MAURICIO) I-39 INFECCIÓN DE INJERTO VASCULAR AÓRTICO POR CÁNDIDA (AMAYA NICOLÁS, JARAMILLO PABLO, RUIZ PAULA) I-40 SÍNDROME INVASIVO POR KLEBSIELLA PNEUMONIAE HIPERMUCOVISCOSA. UNA VARIANTE CLINICA AGRESIVA (PUENTES CASTRILLON MARIA ELCY, TINJACA MONTAÑO KARENT MARGARITA, DOMINGUEZ RUIZ JUAN DIEGO, PUENTES CASTRILLON JOSE JOVANY, SALINAS CORTES DIEGO FERNANDO) I-41 FIEBRE DE ORIGEN DESCONOCIDO COMO MANIFESTACIÓN DE ENFERMEDAD DE CASTLEMAN Y SARCOMA DE KAPOSI EN PACIENTE CON VIH (AMAYA NICOLÁS, RUIZ PAULA, RUMBO JOSÉ) I-42 CROMOMICOSIS (PRETTEL JOSÉ, CAMACHO FRANCISCO, COGOLLO MARYSABEL, RAMÍREZ DIANA, BOLAÑO LUIS, BAZA LISBETH, DOMÍNGUEZ FABIÁN, RODRÍGUEZ REINHARD) I-43 MAL DE POTT EN PACIENTE INMUNOCOMPETENTE (BUSTOS MARLON, GARCÍA JUAN DAVID, SANCHEZ PAULA MARÍA, AGREDA DIANA) I-44 VASCULITIS DEL SISTEMA NERVIOSO CENTRAL POR CITOMEGALOVIRUS EN PACIENTE INMUNOCOMPETENTE (ALZATE JOHN ALEXANDER, ARIAS DANIEL RICARDO, LÓPEZ JESSICA ANDREA) I-45 CRIPTOCOCOSIS CEREBELOSA: UNA FORMA INUSUAL DE PRESENTACION (BRAVO PADILLA VÍCTOR, OCAMPO JOSÉ MAURICIO, CASANOVA MARÍA EUGENIA, OSORIO CINDY VERÓNICA) I-46 CARACTERIZACIÓN DEL PERFIL INFECCIOSO DE PACIENTES CON ENFERMEDADES AUTOINMUNES ATENDIDOS EN CENTRO ESPECIALIZADO (DÍAZ-CORONADO JUAN C, ROJAS-VILLARRAGA ADRIANA, HERNANDEZ-PARRA DEICY, PEREZ-ESTRADA PAULA, BETANCURVÁSQUEZ LAURA, LACOUTURE-FIERRO JORGE, GONZALEZHURTADO DANIEL, GONZALEZ- ARANGO JUANITA, URIBE- ARANGO LAURA, GAVIRIA-AGUILAR MARIA C, PINEDA-TAMAYO RICARDO A. ) I-47 SÍNDROME DE WEIL: A PROPÓSITO DE UN CASO DE LEPTOSPIROSIS (PATIÑO LUISA, BUSTOS MARLON, BUSTAMANTE ÁLVARO, RODRIGUEZ MARTHA PATRICIA) I-48 ENDOCARDITIS FUNGICA DE VÁLVULA TRICUSPIDEA PROTÉSICA EN PACIENTE INMUNOSUPRIMIDO NO USUARIO DE DROGAS ENDOVENOSAS (PLATA JUAN, ARAGÓN DIANA, NARANJO JULIÁN, NOREÑA IVAN) I-49 EPIDEMIOLOGIA DE LA LEPTOSPIROSIS EN EL DEPARTAMENTO DEL HUILA DURANTE LOS AÑOS 2011 A 2017 (ARCE POLO ANGIE VANESSA, CHICA POLANIA MARIA VALENTINA, CEDEÑO CHACÓN GUSTAVO, GÓMEZ-CERQUERA JUAN MANUEL, TAFURT-CARDONA YALIANA) I-50 ESPECTRO CLÍNICO DE LA SIMBIOSIS VIH Y CRIPTOCOCO EN UN HOSPITAL PÚBLICO DE ALTA COMPLEJIDAD DE LA CIUDAD DE MEDELLÍN (CALLE-ESTRADA MATEO, BERRIO-MEDINA INDIRA, JIMÉNEZTABARES JULIANA, JARAMILLO-ARROYAVE DANIEL) I-51 IDENTIFICACIÓN DE MYCOBATERIUM BOVIS EN PACIENTES CON DIAGNOSTICO DE SEROSITIS TUBERCULOSA EN UN HOSPITAL DE CONCENTRACIÓN DE LA CIUDAD DE MÉXICO (YAMILE JURADO-HERNANDEZ, ALEJANDRO HERNÁNDEZ-SOLIS, MARIBEL GONZÁLEZ-VILLA, ERNESTO RAMÍREZ-GONZÁLEZ, HELEODORA GONZÁLEZ-GONZÁLEZ, RAÚL CÍCERO-SABIDO) I-52 UTILIDAD DE LOS MÉTODOS DIAGNÓSTICOS EN PACIENTES CON SEROSISTIS POR M. TUBERCULOSIS, EN UN HOSPITAL DE CONCENTRACIÓN DE LA CIUDAD DE MÉXICO (YAMILE JURADO-HERNANDEZ, ALEJANDRO HERNÁNDEZ-SOLIS, HELEODORA GONZÁLEZ-GONZÁLEZ, MARIBEL GONZÁLEZ-VILLA, ERNESTO RAMÍREZ-GONZÁLEZ, ARTURO REDING-BERNAL, RAÚL CÍCERO-SABIDO) I-53 HIPERINFECCIÓN POR STRONGYLOIDES EN PACIENTE CON TRASPLANTE DE HÍGADO (MANCERA PEDRO, MATEUS JUAN CAMILO, CASTAÑEDA XIMENA, MUGNIER JAQUELINE, HERNÁNDEZ ÁNGELA) I-54 HISTOPLASMA Y VIH: ANÁLISIS CLÍNICO Y DE LABORATORIO DE 20 PACIENTES EN HOSPITAL PUBLICO DE ALTA COMPLEJIDAD. (JIMÉNEZ-TABARES JULIANA, BERRIO-MEDINA INDIRA, CALLEESTRADA MATEO, JARAMILLO-ARROYAVE DANIEL) I-55 TUBERCULOSIS, RECONSTITUCION INMUNE E HISTOPLASMOSIS. UNA TRIADA POCO USUAL (GUERRA HAROL, BRICEÑO OSCAR, CORTES CAMILO) I-56 EMPIEMA NECESSITATIS POR ENTEROBACTERIAS (SALINAS-CORTES DIEGO FERNANDO, PERDOMO DANIELA, SALAMANCA-MONTILLA JHON F, MONDRAGÓN-CARDONA ALVARO) I-57 ASPERGILOSIS PULMONAR INVASIVA EN PACIENTE INMUNOCOMPETENTE (MEDINA AHUMADA PATRICIA, HERNÁNDEZ DANIEL) I-58 INFECCIÓN POR VARICELA ZOSTER DISEMINADA COMPLICADA CON HEPATITIS EN PACIENTE INMUNOCOMPETENTE (MEDINA AHUMADA PATRICIA, HERNÁNDEZ DANIEL) I-59 OSTEOMIELITIS DEL PUBIS (SIERRA UMAÑA SEBASTIÁN FELIPE, MUÑOZ ROSSI FELIPE ALEJANDRO, CASTILLO RODRÍGUEZ CRISTIAN ALEJANDRO, SALINAS MENDOZA SEBASTIAN, ALVEAR REALPE JONATHAN AMBROSIO, LÓPEZ DONATO DIEGO FERNANDO)

Background:CXCR5+PD-1hifollicular helper (Tfh) and CXCR5-PD-1hiperipheral helper (Tph) T cells play an important role in the pathogenesis of Rheumatoid Arthritis (RA) by providing help to autoantibody secreting B cells. Whereas Tfh cells typically dwell in the germinal centers of lymphoid organs, Tph cells accumulate at inflamed tissues. An increased frequency of Tph cells and of circulating counterparts of Tfh cells have been described in the peripheral blood of patients with seropositive RA.Objectives:To examine the effect of treatment escalation using biological agents (TNF blockers or abatacept), on the frequency of circulating Tfh (cTfh) and Tph (cTph) cells in RA.Methods:Peripheral blood was drawn from seropositive RA patients with an incomplete response to csDMARDS (n=29) who initiated biological therapy with TNF blockers (TNFb) (n= 17) or abatacept (n= 12), prescribed based on routine clinical practice. cTfh and cTph cell frequencies were determined by flow cytometry of freshly isolated PBMCs at the basal visit and 6 months after starting treatment escalation. For each patient, an age and gender-matched healthy control (HC) was also studied at both time points (n=29).Results:As compared with HC, active RA patients receiving csDMARDs demonstrated a baseline increased frequency of both cTfh and cTph cells. A significant improvement of disease activity as determined by the DAS28 score (ΔDAS28>2.0) was apparent in all of the patients 6 months after initiating biologicals. At that time point, a significant reduction of the previously elevated cTph cell frequency was observed in both treatment groups. However, cTfh cells remained elevated in patients receiving TNFb notwithstanding a good therapeutic response, whereas subjects receiving abatacept experienced a significant abatement of their cTfh cell frequency. Experimental variation of the cTfh and cTph cell numbers in HC was minimal.Conclusion:Abatacept but not TNFb, are able to bring down cTfh cell numbers in RA. This indicates that costimulation blockade can help attain an immunological remission, whereas TNF neutralization may allow a persistent pathogenic germinal center overactivity. At the same time, treatment with both abatacept and TNF blockers results in a downmodulation of the previouly elevated cTph cell numbers, in parallel with the remitting local joint inflammation.References:[1]Simpson N et al, Arthritis Rheum 2010; Craft J, Nat Rev Rheumatol 2012; Arroyo-Villa I et al., Arthritis Res Ther 2014; Rao DA et al., Nature 2017.Disclosure of Interests:Paula Fortea-Gordo Grant/research support from: BMS, Diana Peiteado: None declared, Alejandro Villalba: None declared, Maria-Jose Santos-Bornez Grant/research support from: BMS, Laura Nuño: None declared, Irene Monjo: None declared, Alejandro Balsa Grant/research support from: BMS, Roche, Consultant of: AbbVie, Gilead, Lilly, Pfizer, UCB, Sanofi, Sandoz, Speakers bureau: AbbVie, Lilly, Sanofi, Novartis, Pfizer, UCB, Roche, Nordic, Sandoz, Maria-Eugenia Miranda-Carus Grant/research support from: BMS, Roche

FICHA TÉCNICA Fecha 8-15 noviembre 2017 Lugar Escuela Técnica Superior de Arquitectura de Granada Organización y profesorado David Arredondo Garrido. Profesor ETSA, Universidad de Granada. Coordinador. Domingo Campillo García. Profesor Universidad Murcia. Marisa Mancilla Abril. Profesora BBAA, Universidad Granada. Ethel Baraona Pohl. Dpr-Barcelona. Profesora invitada. Antonio Collados Alcaide. Profesor BBAA, Universidad de Granada. Alumnos participantes Lorena Iáñez Costela, Ana Abril Prieto, Javier Pleguezuelos Tenorio, Mario Sánchez Samos, Jesús Villar Quintana, Eugenia Winschu, Diego Lidón Segura, Paula Cuesta Pérez, Blanca Rodríguez Huertas, Patricia Huertas García, Laura Muñoz González, Marta Juste González, Alejandro Rivero Collado, David Gómez Martín, Alejandro Pérez García, Francisco Adame Pedrajas, Alba Jiménez Navas, Mario Martínez Santoyo. Entidades colaboradoras Departamento de Construcciones Arquitectónicas. Universidad de Granada. Vicerrectorado de Investigación y Transferencia. Universidad de Granada. Escuela Técnica Superior de Arquitectura de Granada. Facultad de Bellas Artes de la Universidad de Granada. Faculta de Bellas Artes de la Universidad de Murcia. Grupo de investigación HUM813. Arquitectura y Cultura Contemporánea.

La región de los Altos Norte se ubica en la parte noreste del estado de Jalisco dentro de la cuenca de Río Verde en la región Hidrológica Lerma - Santiago. En esta región, el principal producto del sector ganadero es el huevo para plato que representa el 49.8% de la producción total (2013). Gran parte de los residuos generados en la región por la actividad doméstica, pecuaria e industrial no son manejados adecuadamente ocasionando graves deterioros ambientales. En el presente trabajo se comparan los análisis de 20 puntos de muestreo de aguas superficiales distribuidos en los 8 municipios que conforman la región en dos ocasiones (2014 y 2016), detectándose cierto grado de contaminación en los cuerpos de agua estudiados en todos los municipios. Los que presentan mayor grado de contaminación son: Lagos de Moreno, San Juan de Los Lagos, Unión de San Antonio, Villa Hidalgo y en la última evaluación San Diego de Alejandría, los municipios con menor grado de contaminación son Encarnación de Díaz, Ojuelos y Teocaltiche.

Background:Infections are the most common adverse event of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA). In GiACTA study(1),serious infections were observed in 7% (9.6/100 patient-years) of patients who received TCZ weekly. Randomized clinical trials (RCTs) are conducted under highly standardized design excluding some real-world patients. Therefore, adverse events may be underestimated in RCTs. In our series of real-life, serious infections occurred in 11.9% (10.6/100 patient-years)(2).Objectives:In a wide series of GCA of clinical practice treated with TCZ, we assess the frequency, type and predisposing factors of serious infections.Methods:Multicenter study of 134 patients diagnosed with GCA, all of them refractory to conventional therapy, treated with TCZ. Serious infection was considered when a life-threatening infection, fatal, or requiring hospitalization occurred, intravenous antibiotics were required, or the infectious process led to persistent or significant disability.Results:16 of 134 (11.9%, 10.6/100 patient-years) patients developed serious infections during follow-up. The most frequent infections were pneumonia (n=4), urinary tract infection (n=4), and facial herpes zoster (n=2). At TCZ onset, serious infections were more frequent in older patients (74.3±9.6 vs 72.9±8.7 years), with a longer GCA evolution (20 [4.3-45.6] vs 13 [5-29.3] months), with visual manifestations (43.75% vs 17.8%) and a higher dose of prednisone at TCZ onset (30.4±15.5 vs 21.1±16.1 mg/day) (TABLE). Presence of comorbidities were similar in both groups. 13 of the 16 patients who had infections received a dose of prednisone greater than 15 mg/day (16.3/100 patient-years) compared to 3 patients under treatment with less than 15 mg/day of prednisone (4.2/100 patient-years).Conclusion:The age, GCA duration, ocular involvement and the dose of glucocorticoids, at TCZ onset, seem to be predisposing factors related to an increased risk of developing serious infections in GCA patients.References:[1]Stone JH, et al. N Engl J Med. 2017; 377:317-28.[2]Calderón-Goercke M et al. Semin Arthritis Rheum 2019 Aug;49(1): 126-135.TABLESERIOUS INFECTIONS(n=16)WITHOUT SERIOUS INFECTIONS(n=118)pBASAL FEATURES AT TCZ ONSETGENERAL FEATURES Age, years, mean± SD74.3±9.672.9±8.70.552 Sex, female/male n(%)13/388/300.760 Time from GCA diagnosis to TCZ onset (months), median [IQR]20[4.3-45.6]13[5-29.3]0.604COMORBIDITIES Hypertension, n(%)9(56)86(73)0.551 Diabetes, n(%)3(19)39(33)0.677 Chronic kidney disease, n(%)3(19)27(23)0.512CLINICAL FEATURES OF GCA PMR, n(%)9(56.25)64(54.2)0.879 Aortitis, n(%)5(31.25)53(45)0.301 Visual manifestations, n(%)7(43.75)21(17.8)0.017CORTICOSTEROIDS AT TCZ ONSET Prednisone dose mg/d, mean (SD)30.4±15.521.1±16.10.031Disclosure of Interests:Monica Calderón-Goercke: None declared, D. Prieto-Peña: None declared, Santos Castañeda: None declared, Clara Moriano: None declared, Elena Becerra-Fernández: None declared, Marcelino Revenga: None declared, Noelia Alvarez-Rivas: None declared, Carles Galisteo: None declared, Águeda Prior-Español: None declared, E. Galindez: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Eva Salgado-Pérez: None declared, Vicente Aldasoro Speakers bureau: Roche, Abbvie, MSD, UCB, Pfizer, Menarini, Grunenthal, Gebro, Novartis, Janssen, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Susana Romero-Yuste: None declared, J. Narváez: None declared, Catalina Gomez-Arango: None declared, Eva Perez-Pampín: None declared, Rafael Melero: None declared, Francisca Sivera: None declared, Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Alejandro Olive: None declared, María Álvarez del Buergo: None declared, Luisa Marena Rojas: None declared, Carlos Fernández-López: None declared, Francisco Navarro: None declared, Enrique Raya: None declared, Beatriz Arca: None declared, Roser Solans-Laqué: None declared, Arantxa Conesa: None declared, Carlos Vázquez: None declared, Jose Andrés Román-Ivorra: None declared, Pau Lluch: None declared, Paloma Vela-Casasempere: None declared, Carmen Torres-Martín: None declared, Juan Carlos Nieto Speakers bureau: Pfizer, Abbvie, MSD, Novartis, Janssen, Lilly, Nordic Pharma, BMS, Gebro, FAES Farma, Roche, Sanofi, Carmen Ordas-Calvo: None declared, Cristina Luna-Gomez: None declared, Francisco J. Toyos Sáenz de Miera: None declared, Nagore Fernández-Llanio: None declared, Antonio García: None declared, Carmen González-Vela: None declared, Javier García-Fernández: None declared, Patricia Vicente-Gómez: None declared, Ángel García-Manzanares: None declared, Norberto Ortego: None declared, Francisco Ortiz-Sanjuán: None declared, Montserrat Corteguera: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD

Background:Tocilizumab (TCZ) is the only biological agent approved in Giant Cell Arteritis (GCA). There is general agreement on the initial and the standard maintenance dose of TCZ. However, information on duration and optimization of TCZ in GCA is scarce.Objectives:Our aim was to assess efficacy and safety of TCZ therapy optimization in an unselected wide series of GCA in clinical practice.Methods:Multicenter study, 134 patients with GCA who received TCZ due to inefficacy/adverse events of previous therapy. Once complete remission was reached and based on a shared decision between patient and physician TCZ was optimized in some cases. Optimization was done by decreasing the dose and/or prolonging the TCZ dosing interval progressively.Results:134 GCA patients treated with TCZ (101w/33m); mean age 73.0±8.8 years. TCZ was administered IV to 106 (79.1%) patients and SC to 28 (20.9%). TCZ was optimized in 43 (32.1%) patients. No demographic, clinical manifestations or laboratory data differences had been found at TCZ onset (TABLE). After a follow up of 12 [6-15.5] months, and a complete remission for 6 [3-12] months; the first TCZ optimization was performed. Median prednisone dose at first TCZ optimization was 2.5 [0-5] mg/day. TCZ IV was optimized from 8 to 4 mg/kg/4weeks in 12 of 106 (11.3%) and from 162 mg/SC/week to 162 mg/SC/2weeks in 9 of 28 (32.1%) cases. Five (11.6%) of the 43 optimized cases relapsed. In 4 cases, the relapses were treated increasing TCZ up to the pre-optimization dose, in 1 case the route of administration was change (4 mg/kg/4week to 162 mg/SC/week). In 8 of 43 optimized patients (18.6%), it was possible to withdraw TCZ after complete remission for 30 [16.25-45.75] months. Regarding adverse events and severe infections were similar in both groups. The mean TCZ treatment costs were lower in the optimized group.Conclusion:Once remission is reached in GCA patients under TCZ treatment, optimization of TCZ may be performed. Based on our experience it could be performed by reducing the dose with IV TCZ or by prolonging dosing interval with SC TCZ.References:[1]Calderón-Goercke M et al. Semin Arthritis Rheum 2019 Aug;49(1): 126-135.TABLE.OPTIMIZED-TCZ GROUP (n=43)NON-OPTIMIZED TCZ GROUP (n=91)pBASAL FEATURES AT TCZ ONSETGENERAL FEATURESAge, years, mean± SD68.9±8.771.4±8.50.125Sex, female/male n(%)32/1068/240.779Time from GCA diagnosis to TCZ onset (months), median [IQR]19.5[7.75-45]10.5[4 – 25]0.047SYSTEMIC MANIFESTATIONSFever, n(%)1(2.4)8(8.7)0.176Constitutional syndrome, n(%)11(26.2)19(20.7)0.476PMR, n(%)18(42.9)56(60.9)0.052ISCHEMIC MANIFESTATIONSVisual involvement, n(%)5(11.9)23(25)0.084Headache, n(%)26(61.9)42(45.7)0.081Jaw claudication, n(%)1(2.4)11(12)0.072CORTICOSTEROIDS AT TCZ ONSETPrednisone dose, mg/d mean (SD)15.1±11.125±17.40.001FOLLOW-UP ON TCZ THERAPY (MONTHS), MEDIAN [IQR]24[18-27]6 [3-18]0.000Relapses, n(%)5(11.6)5(5.5)0.207End follow-up remission, n(%)40(93)84(92)0.99Severe side efects, n(%)14(32.6)22(24.2)0.307Seriuos infections, n(%)6(14)10(11)0.878Cost, (mean) euros per yearIVSC7 538.47 329.011 726.411 726.4--Disclosure of Interests:Monica Calderón-Goercke: None declared, D. Prieto-Peña: None declared, Santos Castañeda: None declared, Clara Moriano: None declared, Elena Becerra-Fernández: None declared, Marcelino Revenga: None declared, Noelia Alvarez-Rivas: None declared, Carles Galisteo: None declared, Águeda Prior-Español: None declared, E. Galindez: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Eva Salgado-Pérez: None declared, Vicente Aldasoro Speakers bureau: Roche, Abbvie, MSD, UCB, Pfizer, Menarini, Grunenthal, Gebro, Novartis, Janssen, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Susana Romero-Yuste: None declared, J. Narváez: None declared, Catalina Gomez-Arango: None declared, Eva Perez-Pampín: None declared, Rafael Melero: None declared, Francisca Sivera: None declared, Alejandro Olive: None declared, María Álvarez del Buergo: None declared, Luisa Marena Rojas: None declared, Carlos Fernández-López: None declared, Francisco Navarro: None declared, Enrique Raya: None declared, Beatriz Arca: None declared, Roser Solans-Laqué: None declared, Arantxa Conesa: None declared, Carlos Vázquez: None declared, Jose Andrés Román-Ivorra: None declared, Pau Lluch: None declared, Paloma Vela-Casasempere: None declared, Carmen Torres-Martín: None declared, Juan Carlos Nieto Speakers bureau: Pfizer, Abbvie, MSD, Novartis, Janssen, Lilly, Nordic Pharma, BMS, Gebro, FAES Farma, Roche, Sanofi, Carmen Ordas-Calvo: None declared, Cristina Luna-Gomez: None declared, Francisco J. Toyos Sáenz de Miera: None declared, Nagore Fernández-Llanio: None declared, Antonio García: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD

RESUMENA partir de la investigación-creación “Flaubert 20 rutas” (el registro en video de diferentes intervenciones en el transporte público de Bogotá) se pone de manifiesto cómo los buses se pueden convertir en un escenario móvil para el teatro espontáneo. Este contexto da lugar a las reflexiones de una actriz, adaptadas de textos de Gustave Flaubert que tratan de la urbanidad y convivencia social en lo que él llama la buena sociedad. Se establece la identificación de un espacio escénico habitado cotidianamente por pasajeros que al mismo tiempo son personajes reconocibles del entorno urbano. Desde la óptica de una videograbadora se observa que es el propio público el que decide entrar en el juego, asumiendo y reconociendo el rol de espect-actor (Boal) de circunstancias cotidianas. Se comprueba desde una mirada irónica cómo aparecen, en estas situaciones teatrales, concomitancias antropológicas, culturales y políticas.PALABRAS CLAVESFlaubert, buses, ciudad, teatralidad, tránsito, Bogotá. KAUGSAI- PUREI- KAWACHEI: FLAUBERT SUGLLAPIKai tapuchikuna kallarreuramanda- rurakararei “ Flaubert iska chunga purei” Kaipe kawachimi imasami purrekuna autokuna Bogotape. Kai autokuna Purrenkuname chasama ¡ kasama tukuikuna Kawangapa. Kai kilkape Pudenche kawanga imasam kawache sug iacha warine. Kai kilkai rigchami Ñalla kai iacha runa Gustave Flaubert parlakuskasina tukuikunamanda Imasam llukanche kausanga pai sutichimi kaita suma kuasai tukuikunawa. Kaipi pudenchi kawanga imasam kai alpape purrenkuna tukuipunchakuna Rigsiska runakuna chinigta kausaskakuna. Chimandata pudenchi Kawanga imasam wakachikuna iachaikuna ¡nispa kikinkuna pugchai Kallarrengapa allillingapa ¡ Kawangapa ima ruraimi tia tukui puncha Chasa pudenche iachanga imasam kawarre jirú mainemandapas.IMA SUTI RIMAI SIMIFlaubert, atun agtu, atun pueblo, suma kauachidur, purredugta kauag, Bogotape.CITY-POLITICS-THEATER: FLAUBERT AND SPONTANEOUS THEATER. ABSTRACTThe project of research-creation “Flaubert 20 routes” (the video register of different interventions in public transportation in Bogota) revealed how public buses can be converted into a mobile stage for spontaneous theater. This context gives rise to the reflections of an actress, adapted from texts by Gustave Flaubert dealing with civility and social coexistence in what the he calls the good society. It is a stage inhabited daily by passengers who at the same time are recognizable characters of the urban environment. From the perspective of a video camera we observe that it is the public itself who decides to enter the game, assuming and recognizing the role of spect-actor (Boal) of everyday circumstances. From an ironic standpoint, several anthropological, cultural and political concomitances reveal themselves in these theatrical situations. t Archivo fotográfico: Cristina ALejandra JiménezKEYWORDSFlaubert, buses, city, theatricality, transit, Bogota. POLITIQUE-VILLE-THÉÂTRE: FLAUBERT ET LE THÉÂTRE SPONTANÉ RÉSUMÉLa recherche-création « Flaubert 20 routes » (enregistrement vidéo de différentes interventions dans le transport public à Bogota) a révélé comment les autobus peuvent être convertis en une scène mobile pour le théâtre spontané. Ce contexte donne lieu à des réflexions d’une actrice d’après des textes de Gustave Flaubert traitant la civilité et la coexistence sociale dans ce qu’il appelle la bonne société. On identifie un espace scénique habité quotidiennement par des passagers qu’au même temps sont des caractères reconnaissables dans l’environnement urbain. Du point de vue d’un magnétoscope, on observe que c’est le public lui-même qui décide d’entrer dans le jeu, en assumant et en reconnaissant le rôle de spect-acteur (Boal) des circonstances de tous les jours. On constate avec de l’ironie comment il y apparaît dans ces situations théâtrales des concomitances anthropologiques, culturelles et politiques.MOTS CLÉSFlaubert, autobus, ville, théâtralité, transit, Bogotá.CIDADE - POLÍTICA - TEATRO: FLAUBERT E O TEATRO ESPONTÂNEO RESUMOA partir da Investigação-Criação “Flaubert 20 rutas” (Flaubert 20 rotas) (o registro em vídeo de diferentes intervenções no transporte público de Bogotá) se põem de manifesto como os ônibus podem se converter em um Cesário móvil para o teatro espontâneo. Este contexto dá lugar às reflexões de uma atriz, adotadas de textos de Gustave Flaubert que tratam da urbanidade e convivência social no que ele chama a boa sociedade. Estabelece a identificação de um espaço cênico habitado cotidianamente pelos passageiros que ao mesmo tempo são personagens reconhecíveis do entorno urbano. Desde a óptica de um vídeo-gravador se observa que é o próprio público o que decide entrar no jogo, assumindo e reconhecendo o papel de espectador (Boal) de circunstâncias cotidianas. Comprova desde um olhar irônico como aparecem, nestas situações teatrais, concomitâncias antropológicas, culturais e políticas.PALAVRAS CHAVESFlaubert, ônibus, cidade, teatralidade, trânsito, Bogotá.

Background:Infectious diseases are increased in patients with rheumatic disorders; vaccination improves morbidity and mortalityObjectives:The aim of this study was to describe the frequency of vaccination in patients with rheumatic disorders and to compare the results with those obtained in 2009 and 2013 in a similar population. We also identified factors leading to lack of vaccination and patients beliefs on vaccines.Methods:Multicentric cross sectional study in patients with autoinmune diseases from external rheumatology offices. Evaluation of vaccination status and patients´ knowledge about vaccines were studied. A comparative analysis was carried out with the series registered in 2009 and 2013 in a similar population.Results:179 patients (158 female, 88.3% and 21 male, 11.7%) were evaluated. Median age was 52 years. Main pathologies were: Rheumatoid Arthritis 65.9% (n:118), Systemic Lupus Erythematosus 11.7% (n:21), Systemic Sclerosis 3.9% (7), Sjogren Syndrome n = 3.4% (n:6), other diseases 15% (n: 27). Median disease duration: 8.87 years. Ninety three percent of patients (n:167) were taking inmunomodulators and 36.8% (n: 66) were using oral corticosteroids (20mg/day or less); 26,8% patients (n: 48) were receiving biological therapies. Vaccination frequency in the population was: Influenza 82% (147); 13-valent conjugate pneumococcal 69.3% (124), 23-valent pneumococcal 64.2% (115) and hepatitis B 62% (111). Comparative with 2009 and 2013 series there was an increase in the rate of vaccinated patients: influenza (82% vs. 39,1% and 74,2% respectively), antineumococcal (64% vs. 17% and 29%) and hepatitis B (62% vs. 6,7% and 26,7%).Reasons for non-vaccination were absence of medical indication (41% of patients for hepatitis B; 32% for 23-valent pneumococcal; 38% for 13-valent pneumococcal and 34% for influenza).139 patients (77, 7%) knew the benefits of vaccines, 164 (91, 6%) thought vaccines are useful; 134 (74,9%) reported that vaccines may decrease dying probability, 155 (86,5%) thought that vaccines are effective to prevent diseases and 149 patients (83,2%) believed that they prevent serious infections. 71 patients (39%) believed that vaccines can lead to serious consequences and 99 (55,3%) that they are more likely to acquire infections than the rest of the population.Conclusion:Frequency of vaccination has increased since 2009 but there is still misinformation regarding vaccines risks and benefits. Promotion and information is essential to improve adherence.References:[1]2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Furer V, et al. Ann Rheum Dis 2020;79:39–52[2] Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Friedman MA et al. Rheum Dis Clin North Am. 2017 Feb; 43 (1):1-13.[3] Recommendations and barriers to vaccination in systemic lupus erythematosus. Garg M et al. Autoimmun Rev. 2018 Oct; 17 (10):990-1001.[4] Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Papadopoulou D. et al. Rheumatol Int. 2014 Feb;34 (2):151-63.[5] Guías de recomendaciones de prevención de infecciones en pacientes que reciben modificadores de la respuesta biológica. Jordán R. Et al. Rev Arg Reumatol. 2014; 25 (2): 08-26.Disclosure of Interests:Malena Viola: None declared, Alejandro Benitez: None declared, Cecilia Garbarino: None declared, Gonzalo Rodriguez: None declared, Federico Benavidez: None declared, Claudia Peon: None declared, Eliana Soledad Blanco: None declared, Hernan Molina: None declared, Gimena Gómez: None declared, griselda redondo: None declared, Maria DeLaVega: None declared, Dario Mata: None declared, Augusto Riopedre: None declared, Osvaldo Messina Speakers bureau: Amgen; Americas Health Foundation; Pfizer

Background:Interstitial Lung Disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Several conventional disease-modifying anti-rheumatic drugs (cDMARDs) and biologic (b) DMARDs may induce or impaired ILD-RA. Abatacept (ABA) may be useful in ILD-RA (1).Objectives:To assess the efficacy and safety of ABA in a large series of ILD-RA for a long-term follow-up.Methods:Multicenter open-level study of ILD-RA treated with at least 1 dose of ABA. ILD was diagnosed by high-resolution computed tomography (HRTC). We study these outcomes: a) 1-point change Modied Medical Research Council (MMRC); b) forced vital capacity (FVC) and/or DLCO improvement or decline ≥10%; c) change in HRCT, d) change in DAS28. e) Prednisone dose. Values were collected at 0, 3, 6, 12 and then every 12 months.Results:We studied 263 patients (150 women/113 men) (mean age;64.6±10 years), with ILD-RA. At ABA-onset they were smokers or exsmoker (53.8%), positive APCC (88.6%), median [IQR] duration of ILD of 12 [3-41.25] months, mean DLCO (65.7±18.3) and FVC (85.9±21.8).The ILD-pattern were usual interstitial pneumonia (UIP) (40.3%), non-specific interstitial pneumonia (NSIP) (31.9%) and others (27.8%).ABA was prescribed at standard subcutaneous (125 mg/w) in 196 (74.5%) or intravenously (10 mg/kg/4 w) in 67 (25.5%); in monotherapy (n=111) or combined with cDMARDs (n=152); especially leflunomide (n=55), MTX (n=46), or antimarials (n=21).After a mean follow-up of 22.7±19.7 months most outcomes remain stable (Figure). Moreover, DAS28 improved from 4.5±1.5 to 3.1±1.3; prednisone dose reduced from a median 7.5 [5-10] to 5 mg [5-7.5] and retention rate was 76.4%. The main adverse effects were serious infections (n=28), neoplasia (n=3), serious infusion reaction (n=1) and myocardial infarction (n=1).Conclusion:ABA seems effective and relatively safe in ILD-RA.References:[1]Fernández-Díaz C et al. Semin Arthritis Rheum. 2018; 48:22-27Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer.CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD

Background:Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA). In this line, several radiological patterns of RA-ILD have been described: i) usual interstitial pneumonia (UIP), ii) nonspecific interstitial pneumonia (NSIP), iii) obliterating bronchiolitis, iv) organized pneumonia and mixed patterns. Abatacept (ABA) could be an effective and safe option for patients with RA-ILD, although the response in the different radiological patterns is not well defined.Objectives:Our aim was to assess the response to ABA in different radiological patterns of ILD.Methods:Observational retrospective multicenter study of RA-ILD treated with ABA. ILD was diagnosed by HRCT and classified by radiological patterns in 3 different subgroups of RA-ILD: a) UIP, b) NSIP and c) “other”. ABA was used sc. or iv. at standard dose. We assessed: a) Dyspnoea (MMRC scale; significant variation ≥1); b) Respiratory function tests (significant changes ≥10% in FVC and DLCO); c) HRCT imaging; d) DAS28 e)prednisone dose.Variables were collected at months 0, 3, 6, 12 months and subsequently every 12 months until a maximum of 60 months.Results:We included 263 patients: 106 UIP, 84 NSIP and 73 others (150 women / 113 men), mean age 64.64±10 years. Total patients positive for RF or CCPA were 235 (89.4%) and 233 (88.6%), respectively. In 26 out of 263 patients, the development of ILD was closely related to the administration of sDMARDs (MTX n = 11 and LFN n = 1) or bDMARDs (ETN n = 5, ADA n = 4, CZP n = 2 and IFX n = 3). Patient characteristics are shown in table 1. Figure 1 shows the evolution of the cases with available data after a mean follow-up of 22.7±19.7 months. Mean DLCO and FVC remained stable in the 3 groups without statistically significant changes, and all the groups showed a statistically significant reduction in DAS28 and prednisone dose.Conclusion:ABA could be a good choice of treatment in patients with RA-ILD independently of the radiological pattern of ILD.Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, R. López-Sánchez: None declared, Edilia García-Fernández: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD

Background:According to the EULAR recommendations, the therapeutic target in patients with RA should be remission (REM). However, no more than 50% of the patients treated with TNF inhibitors (TNFi) attains this outcome. Previous investigations suggested the peripheral blood mononuclear cells (PBMC) as markers associated with the TNFi treatment success1,2. Granulocyte-monocyte colony-stimulating factor (GM-CSF) plays a relevant role in the pathogenesis of rheumatoid arthritis (RA) because it promotes the macrophage differentiation, survival and activation3.Objectives:To analyse the intracellular cytokine production by PBMC and its association with REM attainment after 6 months (m) of TNFi treatment in patients with RA.Methods:This was a prospective bi-center pilot study including 36 patients with RA. PBMC were isolated from patients at baseline and after 6m of treatment with TNFi and cryopreserved until studied. Intracellular cytokine production by PBMC was stimulated in the presence of 2µg/mL brefeldin as follow: monocytes were stimulated with 20ng/mL LPS during 4h; and simultaneously lymphocytes were stimulated with 50ng/mL phorbol 12-myristate 13-acetate (PMA) and 750ng/mL ionomycin during 4h at 37°C. To identify IL-10-producing B cells, PBMC were pre-incubated with 3µg/mL of CpG oligonucleotide during 20h at 37°C prior to stimulation in presence of 2µmol/L monensin. Intracellular cytokine production (TNFα, IL6, GM-CSF, IL10) by the different cell subsets (monocytes, CD4+and CD8+T cells, naïve and memory B cells) was analysed by flow-cytometry. Clinical activity at baseline and after 6m was assessed by DAS28. REM was defined as DAS28≤2.6 at 6m. The association between REM and the change in cytokine production (Δ, 6m-0m) by each PBMC subset was analysed through univariable and multivariable logistic regression models.Results:Seventy-eight percent of the patients were female. After 6m of TNFi treatment, 47% patients attained REM. Univariable analyses was performed to investigate the association between REM and the baseline variables. Male sex (OR: 12.6; 95% CI: 1.35-117.57; p=0.03) and having lower baseline DAS28 (OR: 0.4; 95% CI: 0.19-0.85; p=0.02) were independently associated with attaining REM after 6m of TNFi. In the multivariable analysis, only being male (OR: 19.7; 95% CI: 1.4-273.9; p=0.03) remained independently associated with REM after 6m of treatment. Therefore, further analyses were adjusted by sex. Decreased production of GM-CSF by CD4+T cells percentage was found after 6m of TNFi treatment in REM patients (0m: 6.07%; 6m: 3.87%; p=0.007) while no-REM patients did not show differences with the baseline (0m: 3.70%; 6m: 3.75%; p=0.9). The decrease was significantly associated with attaining REM (OR: 0.56; 95% CI: 0.33-0.95; p: 0.03). No significant association was found between any other analysed intracellular cytokine produced by the different PBMC subsets and REM.Conclusion:GM-CSF intracellular production by CD4+T cells was significantly decreased by TNFi treatment only in patients who attained REM. Therefore, our results suggest that GM-CSF production by CD4+T cells may be a useful marker of REM to TNFi in RA.References:[1] Sobrino C, et al. Ann Rheum Dis. 2019; 78 (S2): A1665.[2] Hernández-Breijo B, et al. Ann Rheum Dis. 2019; 78 (S2): A711.[3] Avci AB, et al. Clin Exp Rheumatol. 2016; 34 (S98), 39-44.Figure. 1:Association between the change in intracellular cytokine production (Δ, 6m-0m) by each PBMC subset and REM. Adjusted logistic regression analyses were performed for each cytokine.Acknowledgments:ISCIII (PI16/00474; PI16/01092)Disclosure of Interests:Borja Hernández-Breijo: None declared, Chamaida Plasencia: None declared, Carlota García-Hoz: None declared, Cristina Sobrino: None declared, Victoria Navarro-Compán Consultant of: Abbvie, Lilly, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Lilly, Novartis, Pfizer, UCB, ANA MARTÍNEZ-FEITO: None declared, Israel Nieto-Gañán: None declared, Paloma Lapuente-Suanzes: None declared, Javier Bachiller-Corral: None declared, Gemma Bonilla: None declared, Cristina Pijoan Moratalla: None declared, Garbiñe Roy: None declared, Mónica Vázquez Díaz: None declared, Alejandro Balsa Grant/research support from: BMS, Roche, Consultant of: AbbVie, Gilead, Lilly, Pfizer, UCB, Sanofi, Sandoz, Speakers bureau: AbbVie, Lilly, Sanofi, Novartis, Pfizer, UCB, Roche, Nordic, Sandoz, Luisa María Villar: None declared, DORA PASCUAL-SALCEDO Grant/research support from: Pfizer, Novartis & Progenika, Speakers bureau: Pfizer, Merck, Novartis, Takeda, Menarini & Grifols, Eulalia Rodríguez-Martín: None declared

Background:In clinical practice no more than 50% of the patients treated with TNF inhibitors (TNFi) achieve remission (REM). Previous investigations suggested that peripheral blood mononuclear cells (PBMC) may be markers associated with the TNFi treatment success1.Objectives:This study aims to analyse the intracellular cytokine production by PBMC and its association with REM achievement after 6 months (m) of TNFi treatment in patients with RA.Methods:This was a prospective study including 62 patients with RA starting the 1st TNFi. PBMC were isolated from patients at baseline and after 6m of treatment with TNFi and cryopreserved until studied. In vitro stimulation and intracellular cytokine production by PBMC was performed as follow: in the presence of 2µg/mL brefeldin and 2µmol/L monensin monocytes were stimulated with 20ng/mL LPS during 4h whereas lymphocytes were stimulated with 50ng/mL phorbol 12-myristate 13-acetate and 750ng/mL ionomycin for 4h at 37°C. To identify IL10-producing B cells, PBMC were pre-incubated with 3µg/mL of CpG oligonucleotide during 20h at 37°C prior to stimulation. Intracellular cytokine production (TNFα, IL6, GM-CSF, IL10) by the different cell subsets (monocytes, CD4+ and CD8+ T cells, naïve and memory B cells) was analysed by flow-cytometry. Clinical activity at baseline and after 6m was assessed by DAS28-ESR. REM was defined as DAS28≤2.6 at 6m. The association between cytokine production by each PBMC subset and REM was analysed through univariable and multivariable logistic regression models. Receiving operating curve (ROC) analysis was used to select the optimal ratio of cytokine production associated with REM status.Results:After 6m of TNFi treatment, 30 (48%) patients achieved REM. No significant differences between REM and non-REM groups were observed for patients’ characteristics at baseline except for DAS28, which was lower in the REM group (non-REM: 5.4±0.9; REM: 4.3±0.9; p<0.0001) (Table 1). Therefore, further analyses were adjusted by baseline DAS28. A lower ratio between calculated with the IL10 and TNFα production by B cells and by CD4+ T cells (IL10 B/TNF CD4) at 6m was found for non-REM patients (non-REM: 0.31 vs REM: 0.54; p=0.007). Based on a ROC analysis, we found that a (IL10 B/TNF CD4)<0.54 at 6 m was significantly associated with a higher probability of non-REM at 6 months (OR: 5.0; 95% CI: 1.1-21.7) (Figure 1).Table 1.Baseline predictors of reduction of disease activity at 12 months from start of abatacept. Linear regression.Baseline patients’ characteristicsTotal patients (n=62)DAS28>2.6(n=32; 52%)DAS28≤2.6(n=30; 48%)p-valueAge (years)53±1253±1352±100.8Female55 (89)30 (94)25 (83)0.2Disease duration (years)8 (4-11)8 (4-12)7 (3-11)0.7RF positive49 (79)23 (72)26 (87)0.1ACPA positive54 (87)26 (81)28 (93)0.2Smoking habit (n=55)0.2Non-smokers26 (47)16 (55)10 (38) Smoker29 (53)13 (45)16 (51)Body mass index (kg/m2)25.9±5.625.8±5.726.0±5.60.9DAS284.9±1.05.4±0.94.3±0.9<0.0001Concomitant csDMARDs60 (97)32 (100)28 (93)0.3MTX [±OD]46 (74)26 (81)20 (67)0.3Only OD14 (23)6 (19)8 (26)0.3Prednisone36 (58)19 (59)17 (57)0.9Conclusion:Our results show that the proinflammatory IL10 B/TNF CD4 ratio is associated with non-REM status. It could be useful to analyse the success of TNFi treatment in patients with RA.References:[1]Rodríguez-Martín E, et al. Front Immunol. 2020; 11: 1913.Acknowledgements:ISCIII (PI16/00474; PI16/01092)Disclosure of Interests:Borja Hernández-Breijo: None declared, Eulalia Rodríguez-Martín: None declared, Carlota García-Hoz: None declared, Victoria Navarro-Compán Speakers bureau: Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB, Cristina Sobrino: None declared, ANA MARTÍNEZ-FEITO: None declared, Israel Nieto-Gañán: None declared, Javier Bachiller-Corral Speakers bureau: Abbvie, MSD, BMS and Roche, Grant/research support from: Pfizer, Paloma Lapuente-Suanzes: None declared, Gemma Bonilla: None declared, Cristina Pijoán-Moratalla: None declared, Mónica Vázquez: None declared, Alejandro Balsa Speakers bureau: Abbvie, BMS, Nordic, Novartis, Pfizer, Sandoz, Sanofi, Roche and UCB, DORA PASCUAL-SALCEDO: None declared, Luisa María Villar: None declared, Chamaida Plasencia Speakers bureau: AbbVie, Lilly, Novartis, Pfizer, Sanofi, Biogen and UCB

Background:Interstitial Lung Disease (ILD) is an extra-articular complication of rheumatoid arthritis (RA) that is associated with increased morbidity and mortality. Conventional disease-modifying drugs (DMARDs) such as methotrexate (MTX) have been implicated in the development and exacerbation of a pre-existing ILD.Objectives:The aim of our study was to check the influence of combined MTX treatment in patients with RA-ILD treated with abatacept (ABA).Methods:National multicentre retrospective registry of 263 patients with RA-ILD treated with ABA. RA was diagnosed according to the ACR classification criteria of 1987 or by the EULAR/ACR criteria of 2010. ILD was diagnosed by high resolution computed tomography (HRCT). In this study we have done a subanalysis of the 46 patients treated with ABA in combination with MTX (ABA+MTX) vs. 217 patients treated with ABA in monotherapy or in combination with other synthetic DMARDs. Efficacy was evaluated according to the following parameters: a) Dyspnoea (MMRC) considering variations ≥ 1; b) Lung function test (LFT) considering variations ≥ 10% in FVC and a variation of DLCO ≥ 10%; c) Imaging test (HRCT) d) DAS28 score e) prednisone dose. Variables were collected at the beginning of the study and at months 3, 6, 12 and then every 12 months until a maximum of 60 months.Results:263 patients with ILD associated with RA were included in the study with mean age 64.64±10 years. RF or CCPA were positive in 235 (89.4%) and 233 (88.6%) cases, respectively, with a mean follow-up of 22.7±19.7 months. Baseline characteristics of both groups are shown in table 1, while data obtained during evolution of this complication are presented in Figure 1.Conclusion:Despite the baseline differences of both groups, the good evolution in the ABA+MTX subgroup suggests that this therapeutic strategy can be a safe combination for patients with RA-ILD.ABA with MTX (n=46)ABA w/t MTX (n=217)PSex (F/M)28/18122/950.625Age (years)65.11±10.216.2±9.80.202RF/CCPA + (%)91.3/91.389.8/90.10.810Smoking or past smoking (%)47.855.10.417Follow-up (months)22.73±18.0022.3±20.850.916DAS28 at baseline4.08±1.514.61±1.470.056DAS28 at last visit3.00±1.463.13±1.310.642Prednisone at baseline, median (IQR) (mg)5 (5-7.5)7.75 (5-15)0.008*Prednisone at the end of study, median (IQR) (mg)5 (1-5)5 (5-7.5)0.032*DLCO at baseline (%)66.85±19.0465.43±18.210.823DLCO at the end of study (%)66.05±20.9565.17±19.720.831FVC at baseline (%)90.06±17.7785.40±21.560.164FVC at the end of study (%)90.58±15,4584.21±21.490.038*Disclosure of Interests:Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Santos Castañeda: None declared, Rafael Melero: None declared, J. Loricera: None declared, Francisco Ortiz-Sanjuán: None declared, A. Juan-Mas: None declared, Carmen Carrasco-Cubero Speakers bureau: Janssen, MSD, AbbVie, Novartis, Bristol Myers Squibb, and Celgene, S, Rodriguéz-Muguruza: None declared, S. Rodrigez -Garcia: None declared, R. Castellanos-Moreira: None declared, RAQUEL ALMODOVAR Speakers bureau: Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer., CLARA AGUILERA CROS: None declared, Ignacio Villa-Blanco Consultant of: UCB, Speakers bureau: Novartis, MSD, Lilly, Sergi Ordoñez: None declared, Susana Romero-Yuste: None declared, C. Ojeda-Garcia: None declared, Manuel Moreno: None declared, Gemma Bonilla: None declared, I. Hernández-Rodriguez: None declared, Mireia Lopez Corbeto: None declared, José Luis Andréu Sánchez: None declared, Trinidad Pérez Sandoval: None declared, Alejandra López Robles: None declared, Patricia Carreira Grant/research support from: Actelion, Roche, MSD, Consultant of: GlaxoSmithKline, VivaCell Biotechnology, Emerald Health Pharmaceuticals, Boehringer Ingelheim, Roche, Speakers bureau: Actelion, GlaxoSmithKline, Roche, Natalia Mena-Vázquez: None declared, C. Peralta-Ginés: None declared, ANA URRUTICOECHEA-ARANA: None declared, Luis Marcelino Arboleya Rodríguez: None declared, J. Narváez: None declared, DESEADA PALMA SANCHEZ: None declared, Olga Maiz-Alonso: None declared, J. Fernández-Leroy: None declared, I. Cabezas-Rodriguez: None declared, Ivan Castellví Consultant of: Boehringer Ingelheim, Actelion, Kern Pharma, Speakers bureau: Boehringer Ingelheim, Actelion, Bristol-Myers Squibb, Roche, A. Ruibal-Escribano: None declared, JR De Dios-Jiménez Aberásturi: None declared, Paloma Vela-Casasempere: None declared, C. González-Montagut Gómez: None declared, J M Blanco: None declared, Noelia Alvarez-Rivas: None declared, N. Del-Val: None declared, M. Rodíguez-Gómez: None declared, Eva Salgado-Pérez: None declared, Carlos Fernández-López: None declared, E.C. Cervantes Pérez: None declared, A. Devicente-DelMas: None declared, Blanca Garcia-Magallon Consultant of: MSD, Speakers bureau: Pfizer, Amgen, Celgene, MSD, Cristina Hidalgo: None declared, Sabela Fernández: None declared, Edilia García-Fernández: None declared, R. López-Sánchez: None declared, S. Castro: None declared, P. Morales-Garrido: None declared, Andrea García-Valle: None declared, Rosa Expósito: None declared, L. Exposito-Perez: None declared, Lorena Pérez Albaladejo: None declared, Ángel García-Aparicio: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD

Encerrando as publicações de 2019, o 3º número da Motricidades: Revista da SPQMH traz 6 textos, sendo 1 artigo de pesquisa, 3 artigos de revisão e 2 ensaios.No Artigo de Pesquisa “Arte popular na região fronteiriça Brasil-Paraguai”, Paulo César Antonini de Souza (Universidade Federal do Mato Grosso do Sul, UFMS, Campo Grande-MS, Brasil) e Maria Carolina Rodrigues (Universidade Federal do Mato Grosso do Sul, UFMS, Campo Grande-MS, Brasil) apresentam os resultados de uma investigação desenvolvida durante o biênio 2016-2017 a fim de identificar manifestações da arte popular na região fronteiriça de Mato Grosso do Sul com o Paraguai, especificamente, a partir das relações entre Ponta Porã (Brasil) e Pedro Juan Caballero (Paraguai).Wagner Wey Moreira (Universidade Federal do Triângulo Mineiro, UFTM, Uberaba-MG, Brasil), Marcus Vinicius Simões de Campos (Universidade Estadual de Campinas, UNICAMP, Campinas-SP, Brasil) e Regina Simões (Universidade Federal do Triângulo Mineiro, UFTM, Uberaba-MG, Brasil), no artigo de revisão intitulado “Motricidade, Corporeidade e Complexidade: diálogos a partir do hemisfério sul” enfatizam a Motricidade como possível meta-ciência ocupada em reconhecer o ser humano que se movimenta intencionalmente na direção de transcender, a Corporeidade como uma atitude a exigir valores diferentes do trato com o corpo mecânico, ainda estudado e ensinado de forma hegemônica na atualidade e a Complexidade como nova forma de perspectivar a vida e os pressupostos axiológicos nela contidos.Em “A proposta da Base Nacional Comum Curricular para o ensino de Arte”, Denise Andrade de Freitas Martins (Universidade Estadual de Minas Gerais, UEMG, Ituiutaba-MG, Brasil) e Maria Aparecida Augusto Satto Vilela (Universidade Federal de Uberlândia, UFU, Pontal-MG, Brasil) discutem a Base Nacional Comum Curricular (BNCC) brasileira, tendo como foco o ensino de arte na Educação Infantil e nos anos iniciais do Ensino Fundamental. A intenção das autoras é suscitar reflexões que contribuam para o exercício crítico e cidadão de ser professor e professora no Brasil.No terceiro artigo de revisão, “Physical activities, sports and sustainability: a reflection on the role of the world surf league”, Tiago Brant de Carvalho Falcão (Universidade de São Paulo, USP, São Paulo-SP) e Ricardo Ricci Uvinha (Universidade de São Paulo, USP, São Paulo-SP), a partir da exposição de iniciativas sustentáveis como: Sustainable Surf, Earth Technologies, The Plastic Pickup, Counter Current Art e The Cigarette Surfboard, apresentam reflexões sobre o papel da liga mundial de surfe na preservação da natureza. Para os autores, a sustentabilidade e a preservação da natureza, que fazem parte do estilo de vida do surfista, podem influenciar as novas gerações de forma a reverter a atual crise climática e ambiental pela qual passa o planeta.“Em busca de movimentos ausentes para motricidades emergentes: a relação entre Epistemologias do Sul e Motricidade Humana”, de autoria de Carlos Nolasco (Universidade de Coimbra, UC, Coimbra, Portugal), parte das Epistemologias do Sul, enquanto proposta de resgate de dimensões epistêmicas e humanas ausentes do espaço hegemônico, e apresentadas como alternativas ao esgotamento da modernidade, para propor uma análise crítica das dinâmicas sociais do desporto, através da operacionalização dos conceitos de sociologia das ausências e de sociologia das emergências, sugerindo a emergência de outro desporto que vá ao encontro da perspectiva da motricidade humana na assunção da complexidade e da transcendência do gesto desportivo.Pensar como o Profissional da área de Motricidade Humana se insere na era da simulação e se apropria dos recursos digitais para atualizar e dinamizar sua prática, representou a motivação para o ensaio “Motricidade (pós)humana e a abordagem sobre o corpo na era da simulação”, de Gisele Maria Schwartz (Universidade Estadual Paulista “Júlio de Mesquita Filho”, UNESP, Rio Claro-SP, Brasil). Para a autora, pensar, na atualidade, o corpo sensível em movimento, em sincronia com a (ciber)cultura, se torna o grande desafio para a Motricidade Humana - tudo o que é novo induz ao risco, mas também, apresenta novas possibilidades de criar.Finalizando este editorial, não poderia deixar de recordar que há dois anos, aproximadamente, durante a Mesa de Abertura do VII Colóquio de Pesquisa Qualitativa em Motricidade Humana: Ecomotricidade e Bem Viver, na Universidade Federal de Sergipe (UFS), em São Cristóvão-SE, lançamos a Motricidades: Revista da SPQMH.Depois de 6 números (v.1, n. 1, 2017; v. 2, n. 1, n. 2 e n. 3, 2018; v. 3, n. 1 e n. 2) da revista, continuamos resistindo às dificuldades!A Motricidades segue adiante, nesse 7º número, expandindo a divulgação científica na área de Educação, em suas interfaces com Artes, Educação Física, Lazer, Meio Ambiente e Saúde, tendo a imensa satisfação de simbolicamente lançá-lo na abertura do VIII Colóquio de Pesquisa Qualitativa em Motricidade Humana: Motricidade e Interculturalidade, na Universidade Pedagógica de Maputo (UPM), Moçambique!Boas leituras, reflexões, debates e, principalmente... engajadas ações! São Carlos-SP, dezembro de 2019MOTRICIDADESRev. SPQMHEditorProf. Dr. Fábio Ricardo Mizuno Lemos(Instituto Federal de São Paulo, Brasil)Editores AssociadosProfa. Dra. Denise Aparecida Corrêa(Universidade Estadual Paulista, Brasil)Prof. Dr. Luiz Gonçalves Junior(Universidade Federal de São Carlos, Brasil)Prof. Dr. Paulo César Antonini de Souza(Universidade Federal do Mato Grosso do Sul, Brasil)Prof. Dr. Victor Lage(Universidade de Brasília, Brasil)Conselho EditorialProf. Dr. Cae Rodrigues(Universidade Federal de Sergipe, Brasil)Profa. Dra. Claudia Foganholi(Universidade Federal Fluminense, Brasil)Profa. Dra. Denise Andrade de Freitas Martins(Universidade do Estado de Minas Gerais, Brasil)Prof. Dr. Elenor Kunz(Universidade Federal de Santa Maria, Brasil)Profa. Dra. Fabiana Rodrigues de Sousa(Centro Universitário Salesiano, Brasil)Prof. Dr. Gilberto Tadeu Reis da Silva(Universidade Federal da Bahia, Brasil)Prof. Dr. Glauco Nunes Souto Ramos(Universidade Federal de São Carlos, Brasil)Profa. Dra. Lílian Aparecida Ferreira(Universidade Estadual Paulista, Brasil)Profa. Dra. Luciane Ribeiro Dias Gonçalves(Universidade Federal de Uberlândia, Brasil)Prof. Dr. Manuel Sérgio Vieira e Cunha(Universidade Técnica de Lisboa, Portugal)Prof. Dr. Marcos Garcia Neira(Universidade de São Paulo, Brasil)Profa. Dra. Petronilha Beatriz Gonçalves e Silva(Universidade Federal de São Carlos, Brasil)Profa. Dra. Regina Maria Rovigati Simões(Universidade Federal do Triângulo Mineiro, Brasil)Prof. Dr. Sergio Alejandro Toro Arévalo(Universidad Austral de Chile, Chile)Profa. Dra. Valéria de Oliveira Vasconcelos(Centro Universitário Salesiano, Brasil)Profa. Dra. Vitória Helena Cunha Espósito(Pontifícia Universid/ade Católica de São Paulo, Brasil)Prof. Dr. Wagner Wey Moreira(Universidade Federal do Triângulo Mineiro, Brasil)

Lectura y contralectura en la Historia de la Lectura es una obra “selectiva y parcial”, comoel mismo autor nos la presenta, que resume las inquietudes, de una larga y reconocidatrayectoria académica, centradas en la historia de la lectura (HL); una obra pensada noúnicamente como referencia encaminada al planteamiento y resolución de casos prácticosde estudio, sino también como problemática de índole existencial de la propia disciplina.

La figura del compositor chileno Juan Orrego Salas (Santiago de Chile, 18 de enero de 1919-Bloomington, Indiana, E.E.U.U., 24 de noviembre de 2019) se alza como una de las personalidades más importantes, influyentes y referenciales de la creación sonora académica de Iberoamérica en el siglo XX. Testigo y coautor del florecimiento de la composición latinoamericana y de los foros panamericanos, Orrego Salas pertenece a la segunda oleada de grandes creadores iberoamericanos del siglo XX que – junto a compositores como el argentino Alberto Ginastera o el panameño Roque Cordero – proyectaron y trascendieron el marco nacionalista al que la música latinoamericana se había visto constreñida después de Heitor Villa-Lobos, los mexicanos Carlos Chávez y Silvestre Revueltas o los cubanos Amadeo Roldán y Alejandro García Caturla. En Orrego Salas confluyen compositor, musicólogo, docente, gestor y crítico musical además de un verdadero adalid de la promoción de la música latinoamericana como fundador del LAMC (Latin American Music Center) en Bloomington, perteneciente a la norteamericana Universidad de Indiana. Un importante rasgo de la personalidad de éste creador chileno es su “españolidad” vertida en varias obras de su catálogo compositivo entre las que destaca la cervantina Palabras de Don Quijote. El presente artículo, producto de dos artículos anteriores que sobre Juan Orrego Salas tuve ocasión de llevar a cabo, pretende ser un homenaje a este factotum musical con motivo del año de su centenario y fallecimiento, 2019. En la primera parte se realiza un breve recorrido por su figura musical cuya pertinencia se explica por el incomprensible desconocimiento que de la creación musical iberoamericana y sus figuras se tiene, en ocasiones, no solo en geografías no americanas sino en los propios países de Latinoamérica. La segunda, y más extensa parte de este escrito, consiste en un análisis de Palabras de don Quijote en la que el compositor chileno proyecta su devoción por el universal autor de Don Quijote de La Mancha, al tiempo que hace suyos los valores del “caballero andante” para transitar su recorrido vital como hombre y creador, ejemplo de honestidad y coherencia ética e intelectual.